Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Summary

The purpose of this pilot study is to evaluate the safety of nanoliposomal irinotecan in combination with 5-FU and leucovorin with paricalcitrol as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma who have progressed on a gemcitabine-based regimen.

General Information

NCT#: NCT03883919
Study ID: 201905201
Trial Phase: Pilot

Trial Sponsor: Washington University, Ipsen Biopharmaceuticals
Therapies Used in This Trial: Fluorouracil, Leucovorin, irinotecan liposome injection, Paricalcitol

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search